Department of Radiology, Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Curr Oncol Rep. 2022 Oct;24(10):1351-1361. doi: 10.1007/s11912-022-01293-1. Epub 2022 May 31.
The incidence of lymphatic leakage (iatrogenic and non-iatrogenic) is growing in cancer population due to the increased complexity of the surgical procedures and improved overall survival in cancer patients. The purpose of this article is to review the contemporary approach in the field of percutaneous lymphatic embolization in cancer patients with lymphatic leaks.
Since the advent of intranodal lymphangiography in 2011 alongside with the MR and CT lymphangiography, the accuracy of diagnosis of the lymphatic diseases has significantly improved significantly. These advancements have triggered a revival of minimally invasive lymphatic interventions. Lymphatic embolization is expanding from the classic indication, thoracic duct embolization, to other lymphatic disorders (chylous ascites, lymphoceles, liver lymphorrhea, protein-losing enteropathy). The growth of lymphatic research and the standardization of the lymphatic interventions require a multidisciplinary and collaborative approach between physicians and researchers.
由于手术复杂性的增加和癌症患者总体生存率的提高,癌症患者的淋巴漏(医源性和非医源性)发病率不断上升。本文旨在综述癌症患者淋巴漏经皮淋巴栓塞治疗领域的当代方法。
自 2011 年淋巴结内淋巴管造影术以及 MR 和 CT 淋巴造影术问世以来,淋巴疾病的诊断准确性显著提高。这些进展引发了微创淋巴介入治疗的复兴。淋巴栓塞从经典的适应证——胸导管栓塞,扩展到其他淋巴疾病(乳糜性腹水、淋巴囊肿、肝淋巴液漏、蛋白丢失性肠病)。淋巴研究的发展和淋巴介入的标准化需要医生和研究人员之间的多学科和协作方法。